2012
Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency
MENENDEZ, Sergio; Suzanne CAMUS; Aida HERRERIA; Ida PARAMONOV; Laura B MORERA et al.Základní údaje
Originální název
Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency
Autoři
MENENDEZ, Sergio; Suzanne CAMUS; Aida HERRERIA; Ida PARAMONOV; Laura B MORERA; Manuel COLLADO; Vladimír PEKAŘÍK; Iago MACEDA; Michael EDEL; Antonella CONSIGLIO; Adriana SANCHEZ; Han LI; Manuel SERRANO a Juan C I BELMONTE
Vydání
AGING CELL, MALDEN, USA, WILEY-BLACKWELL, 2012, 1474-9718
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
Genetika a molekulární biologie
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 5.705
Označené pro přenos do RIV
Ne
UT WoS
Klíčová slova anglicky
induced pluripotent stem; embryonic stem; tumorigenicity; p53; Ink4a; ARF; reprogramming
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 4. 2. 2013 15:42, Olga Křížová
Anotace
V originále
Embryonic stem (ES) cells and induced pluripotent stem (iPS) cells represent a promising therapeutic tool for many diseases, including aged tissues and organs at high risk of failure. However, the intrinsic self-renewal and pluripotency of ES and iPS cells make them tumorigenic, and hence, the risk of tumor development hinders their clinical application. Here, we present a novel approach to limit their tumorigenicity and increase their safety through increased copy number of tumor suppressors. iPS containing an extra copy of the p53 or Ink4a/ARF locus show normal pluripotency, as determined by in vitro and in vivo differentiation assays. Yet, while retaining full pluripotency, they also possess an improved engagement of the p53 pathway during teratocarcinoma formation, which leads to a reduced tumorigenic potential in various in vitro and in vivo assays. Furthermore, they show an improved response to anticancer drugs, which could aid in their elimination in case tumors arise with no adverse effects on cell function or aging. Our system provides a model for studying tumor suppressor pathways during reprogramming, differentiation, and cell therapy applications. This offers an improved understanding of the pathways involved in tumor growth from engrafted pluripotent stem cells, which could facilitate the use of ES and iPS cells in regenerative medicine.